New scan could spot hidden pancreatic cancer spread

NCT ID NCT07217717

Recruiting now Diagnosis Sponsor: SOFIE Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The goal is to see if this scan is more accurate than current methods at finding metastatic disease, which could help doctors plan better treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]FAPI-74 (radioactive diagnostic agent for PET imaging)
What this could lead to: If successful, this scan could help doctors more accurately detect whether pancreatic cancer has spread, leading to better treatment decisions.
What could go wrong: This is still an experimental scan, and it may not prove more accurate than current methods. The trial is relatively small (200 people) and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

City of Hope National Cancer Center
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Helios CR Inc./RadNet
RECRUITING

Cerritos, California, 90703, United States
Hoag Memorial Hospital
RECRUITING

Irvine, California, 92618, United States
Icahn School of Medicine at Mount Sinai
NOT_YET_RECRUITING

New York, New York, 10029, United States
Indiana University Health University Hospital
RECRUITING

Indianapolis, Indiana, 46202, United States
Kettering
RECRUITING

Kettering, Ohio, 45429, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffit Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Stanford University
RECRUITING

Stanford, California, 94305, United States
UCLA
RECRUITING

Los Angeles, California, 90095, United States
UMass/Shields
RECRUITING

Worcester, Massachusetts, 01655, United States
University of Pennsylvania, Perelman School of Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.